Innate Immunity in Allergic Asthma

Part of paid clinical trials in Orlando, Florida.

Sponsor
University of Central Florida
Study ID
NCT06068335
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.

Key Dates

Start date
Oct 18, 2021
Status verified
Dec 2024
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

To determine which parameters of the established type-2 signature obtained in vitro is significantly different between healthy controls, allergic individuals, and asthmatic individuals ex vivo. [ Time Frame: 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Central FloridaOrlandoFlorida32816-

Find similar trials in Orlando, FL

By condition
Asthma
By specialty
PulmonologyLung disease
By research site
University of Central Florida· Orlando, FL

Related Studies